Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imatinib
Drug ID BADD_D01136
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status approved
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D08066
MeSH ID D000068877
PubChem ID 5291
TTD Drug ID D0AZ3C
NDC Product Code 63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII BKJ8M8G5HI
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C29H31N7O
CAS Registry Number 152459-95-5
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oropharyngeal cancer16.19.05.003; 07.21.07.004; 22.08.02.0040.000224%Not Available
Recurrent cancer16.16.01.0150.002239%Not Available
Squamous cell carcinoma of the oral cavity16.13.07.006; 07.21.07.0090.000112%Not Available
Takayasu's arteritis24.12.02.008; 10.02.02.0280.000112%Not Available
Teeth brittle07.09.05.0150.000112%Not Available
Throat cancer16.19.02.007; 22.08.02.0080.000302%Not Available
Concomitant disease progression08.01.03.0640.000280%Not Available
Terminal state08.01.03.0790.000168%Not Available
Ovarian adenoma21.11.01.012; 16.04.03.0050.000112%Not Available
Live birth18.08.02.0070.000280%Not Available
Metastases to heart16.22.02.016; 02.10.01.0020.000280%Not Available
Blast crisis in myelogenous leukaemia16.01.08.002; 01.10.08.0020.004869%Not Available
Gastric antral vascular ectasia24.03.03.028; 07.15.04.0030.001791%Not Available
Pulmonary cavitation22.01.02.0220.000112%Not Available
Bone marrow oedema15.02.01.005; 01.05.01.0190.001231%Not Available
Neuroendocrine tumour16.24.01.009; 05.08.01.0130.000112%Not Available
Small intestinal haemorrhage24.07.02.019; 07.12.03.0020.000302%
Fibrous histiocytoma23.10.01.012; 16.26.01.0120.000224%Not Available
Cardiac ventricular thrombosis02.11.01.008; 24.01.05.0060.000280%Not Available
Disorder of orbit06.08.03.0120.000168%Not Available
Retroplacental haematoma24.07.03.029; 18.02.01.0060.000280%Not Available
Hepatic mass09.01.08.0150.000224%Not Available
Cell death14.11.02.005; 08.03.03.0030.000168%Not Available
Parakeratosis23.03.03.0670.000224%Not Available
Abdominal compartment syndrome24.04.09.009; 07.11.01.0170.000112%Not Available
Bone marrow necrosis24.04.09.002; 01.05.01.0120.000336%Not Available
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.000336%Not Available
Desmoid tumour16.18.01.006; 15.09.01.0050.000728%Not Available
Gastrointestinal erosion07.04.04.0090.000112%Not Available
Diaphragmatic disorder22.09.02.0050.000112%Not Available
The 29th Page    First    Pre   29 30 31 32    Next   Last    Total 32 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene